Covington Advises Cantor Fitzgerald in Signal Genetics Merger

Covington Advises Cantor Fitzgerald in Signal Genetics Merger

November 23, 2016

NEW YORK—Covington is advising Cantor Fitzgerald as financial advisor to Signal Genetics in connection with Signal’s merger transaction with miRagen Therapeutics.

Signal is a commercial stage, molecular diagnostic company that provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of cancer patients. miRagen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative microRNA-targeting therapies for disease.  

The Covington team consists of partner Jack Bodner, associate Allison Schiffman, and law clerk Ian Murray.